Importance and Involvement of Imidazole Structure in Current and Future Therapy

Read full text
Authors: Alexandra Pavel Burlacu, Maria Drăgan, Ovidiu Oniga, Mădălina Nicoleta Matei, Ilioara Oniga, Elena Lăcrămioara Lisă, C. Ştefan, Oana-Maria Dragostin
Cited by: 11
References: 135

Abstract

Imidazole is, from a structural point of view, a heterocycle consisting of three C atoms and two N atoms, belonging to the class of diazoles, having two N atoms at the first and third positions in the aromatic ring. Being a polar and ionizable aromatic compound, it has the role of improving the pharmacological properties of lead molecules, thus being used to optimize their solubility and bioavailability. Imidazole is a constituent of many important biological compounds, like histidine, histamine, and purine compounds, the most widespread heterocyclic compound in nature. In current practice, substituted imidazole derivatives play a major role in antifungal, antibacterial, anti-inflammatory, CNS active compounds, antiprotozoal, as well as anticancer therapy. Thus, imidazole derivatives have demonstrated significant anticancer activities by inhibiting the key metabolic pathways essential for tumor cell growth and survival. Nitroimidazoles, for instance, have been employed as hypoxia-directed therapeutic agents, targeting oxygen-deprived tumor tissues, while mercaptopurine derivatives are well-established in oncological treatments. Structural modifications of the imidazole nucleus have led to the novel compounds exhibiting increased selective cytotoxicity against cancer cells, while sparing normal healthy cells. In accordance with what has been stated, this review highlights recent research on the medicinal and pharmaceutical interest of novel imidazole derivatives, emphasizing their potential in the development of new drugs.

Fields of Study & Subjects

Synthesis and biological activity Cancer Research and Treatment Biochemical and Molecular Research

Publication details

Journal / source
Molecules
Publisher
MDPI AG
Volume
31
Issue
3
Pages
423–423
Publication date
26 January 2026
Language
EN